Explore more publications!

IT Press Releases: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on IT Press Releases.

Press releases published on December 6, 2025

Ant O&M: Streamlining Global ICT Procurement and Deployment as a China Top Networking Equipment Service
Seven Corbett Announces Exclusive 2026 New Year Trip Package in Jim Corbett
Oriental Artisan Elevates Corporate Gifting with Curated Collection of Handcrafted Eastern Treasures
Ainnocence Announces AI Platform for Material Performance Prediction and Process Optimization
Deep Learning Market Growth to Top USD 406 Billion by 2032 | CAGR Projected at 37.8%
Driving with 18.7% CAGR | Computer Vision Market Size Reach USD 82.1 Billion by 2032
Driving with 22.6% CAGR | IoT in Manufacturing Market Reach USD 1,495.65 Billion by 2030
Driving with 28.1% CAGR | NoSQL Market Reach USD 86.3 Billion by 2032
Precision Agriculture Market Share Reach USD 23.05 Billion By 2030
Situation Awareness System Market Reach USD 67.27 Billion by 2030
Enterprise Asset Management Market Forecast to Cross USD 9.9 Billion by 2031 | 11.5% CAGR
Artificial Intelligence of Things (AIoT) Market Set to Hit $1.3 Trillion by 2032 | 30.2% CAGR
Driving with 17.4% CAGR | Hybrid Cloud Market Share Reach USD 480.2 Billion by 2033
Driving with 24.7% CAGR | Lawful Interception Market Reach USD 29.9 billion by 2031
Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
Sapu Nano 宣布推出基于 Deciparticle™ 技术的生物标志物框架,用于识别最可能对静脉注射 Sapu003(一种依维莫司纳米药物)产生反应的肿瘤
Sapu Nano 宣佈由 Deciparticle™ 驅動的生物標記框架,可識別出最有可能對靜脈注射依維莫司納米藥物 Sapu003 產生反應的腫瘤
BioNTechs und OncoC4s selektiver Treg-Modulatorkandidat Gotistobart erzielte klinisch relevanten Gesamtüberlebensvorteil bei Patientinnen und Patienten mit zuvor behandeltem Plattenepithelkarzinom der Lunge
BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions